AGOURA HILLS, Calif.--(BUSINESS WIRE)--Caldera Medical, a leader in the development of implants for the treatment of female Stress Urinary Incontinence, has announced it will introduce three of its newest FDA cleared solutions for SUI, Desara® Mini, Desara® SL, and Desara® Blue, at the American Urogynecologic Society (AUGS) 34th Annual Scientific Meeting running from October 16th through October 19th in Las Vegas, NV.
- Desara® Blue is a blue version of Caldera Medical’s Desara® universal sling system and provides surgeons with their choice of multiple surgical approaches by utilizing reusable instrumentation. The blue color provides exceptional visibility both during and after the procedure.
- Desara® SL utilizes the same proven Desara® mesh in a shorter 12 cm length to minimize the amount of mesh implanted. A shorter 12 cm sling length has been shown to significantly reduce post-operative groin pain, making patients more comfortable while delivering equivalent safety and efficacy as traditional slings.
- Desara® Mini is a mini sling which combines the proven Desara mesh with a secure fixation system that allows for sling placement in a less invasive, single incision procedure.
“We enjoy coming to AUGS as it is an opportunity for us to highlight our broad portfolio of innovative solutions for the treatment of SUI, one of the primary conditions treated by urogynecologists. Since our inception we have focused on providing surgeons with a breadth of choices to meet their needs,” commented Bryon L. Merade, Chairman and CEO, adding “The addition of three new products for the treatment of SUI in 2013, Desara® Mini, Desara® SL, and Desara® Blue, demonstrates our continued commitment to providing our physician customers with the most comprehensive line of solutions for the treatment of Stress Urinary Incontinence.”
Caldera Medical’s other product lines include the Desara® Sling System for treatment of Stress Urinary Incontinence and Vertessa™ Lite, a supple, lightweight yet strong polypropylene mesh for use in abdominal sacrocolpopexy procedures for the treatment of Pelvic Organ Prolapse (POP). Stress Urinary Incontinence, the most prevalent form of incontinence among women, affects an estimated 15 million adult women in the U.S. and incontinence is the second leading cause of institutionalization in older women. Pelvic Organ Prolapse (POP) is one of the most common quality of life conditions facing women with nearly 50% of all women who give birth vaginally developing POP. A woman’s lifetime probability for undergoing a surgical treatment to correct POP is approximately 11%. Abdominal sacrocolpopexy procedures are expected to grow approximately 15% in 2013 due to a shift from transvaginal prolapse repair procedures.
About Caldera Medical
Caldera Medical is dedicated to improving quality of life for women. Caldera Medical develops and markets differentiated surgical implants specifically for the treatment of Stress Urinary Incontinence and Pelvic Organ Prolapse across the gynecology, urology and urogynecology specialties.
Caldera Medical is a privately held company located in Agoura Hills, California. For more information, visit Caldera Medical's Web site at www.calderamedical.com.
